MBL

Anti-CD45.2 (Mouse) mAb-PE

Product Code:
 
MBL-FP20296010
Product Group:
 
Primary Antibodies
Supplier:
 
MBL
Host Type:
 
Mouse
Antibody Isotype:
 
IgG2a κ
Antibody Clonality:
 
Monoclonal
Antibody Clone:
 
104
Regulatory Status:
 
RUO
Target Species:
 
Mouse
Application:
 
Flow Cytometry
Shipping:
 
4°C
Storage:
 
4°C
 

No additional charges, what you see is what you pay! *

CodeSizePrice
MBL-FP20296010100 ug£360.00
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Background:
The 104 monoclonal antibody specifically reacts with the mouse CD45 molecule, the Leukocyte Common Antigen (LCA) which occurs in the alloantigen CD45.2-expressing mouse strains (C57BL/6, CBA, 129, A, AKR, C58, DBA/1, DBA/2, BALB/c, and C3H/He). The 104 monoclonal antibody does not react with the leukocytes of the CD45.1-expressing mouse strains (DA, SJL/J, RIII, and STS/A). The CD45 molecule is a member of the Protein Tyrosine Phosphatase (PTP) family, because its intracellular region contains two PTP domains. The extracellular region?s variability is caused by different levels of glycosylation, and the splicing of the 4, 5, and 6 exons. The isoforms found in the mouse strains depend on the activation state, maturation stage and cell type, and are very important in B and T lymphocytes antigen receptor signal transduction. The 104 antibody inhibits some of the B lymphocytes responses, reduces the serum IgG levels, and influences the autoimmune renal pathology.
Concentration:
0.2 mg/mL
Conjugate:
PE
Formulation:
Phosphate-buffered aqueous solution, ?0.09% Sodium azide, may contain carrier protein/stabilizer, ph7.2.
Target:
CD45.2

Documents

References

Hathcock, K. S., et al., Science. 262, 905-907 (1993) Inaba, K., et al., J Exp Med. 180, 1849-1860 (1994) Hathcock, K. S., et al., J Exp Med. 180, 631-640 (1994)